Journal of Alzheimers Disease & Parkinsonism

Yuriko, J Alzheimers Dis Parkinsonism 2023, 13:5

Short Communication Open Access

Parkinson's Disease: The Motor and Non-Motor Symptoms and Various Treatment Options in Gene Therapy

Andrew Yuriko*

Department of Medicine, University of New South Wales, Kensington, New South Wales, Australia

***Corresponding author:** Andrew Yuriko, Department of Medicine, University of New South Wales, Kensington, New South Wales, Australia, E-mail: andrew@yuriko.com

Received: 30-Aug-2023, Manuscript No. JADP-23-115574; **Editor assigned:** 01-Sep-2023, PreQC No. JADP-23-115574 (PQ); **Reviewed:** 15-Sep-2023, QC No. JADP-23-115574; **Revised:** 22-Sep-2023, Manuscript No. JADP-23-115574 (R); **Published:** 29-Sep-2023, DOI: 10.4172/2161-0460.1000581.

Citation: Yuriko A (2023) Parkinson's Disease: The Motor and Non-Motor Symptoms and Various Treatment Options in Gene Therapy. J Alzheimers Dis Parkinsonism 13: 581.

Description

Parkinson's disease is a neurodegenerative disorder that affects millions of people worldwide, causing a range of motor and non-motor symptoms. While there is no cure for Parkinson's disease, various treatment options aim to manage its symptoms. One promising avenue of research is gene therapy, which holds the potential to address the underlying causes of the disease. In this article, we will explore the current state of Parkinson's gene therapy research, its potential benefits, and the challenges it faces Parkinson's disease primarily results from the progressive degeneration of dopamine-producing neurons in the brain, particularly in a region called the substantia nigra. Dopamine is a neurotransmitter that plays a crucial role in controlling movement and regulating mood. As these neurons expire, individuals with Parkinson's disease experience motor symptoms such as tremors, bradykinesia (slowness of movement), rigidity, and postural instability.

Gene therapy: A potential solution

Gene therapy is an experimental approach that involves altering a person's genes to treat or prevent disease. In the context of Parkinson's disease, gene therapy aims to restore the function of dopamine-producing neurons or protect them from further damage. There are several strategies being explored in the field of Parkinson's gene therapy. This approach involves introducing functional genes into the brain to compensate for the ones that are defective or missing. In the case of Parkinson's disease, researchers are looking at genes involved in dopamine production, such as the GDNF (glial cell-derived neurotrophic factor) gene [1]. CRISPR-Cas9 technology allows for precise editing of DNA, opening up the possibility of correcting genetic mutations associated with Parkinson's disease. While this approach is still in its early stages of development, it holds significant promise. Some gene therapy strategies focus on protecting existing dopamine-producing neurons from further damage. This may involve the delivery of genes that promote cell survival or the production of neuroprotective proteins [2-4].

Progress in parkinson's gene therapy

While gene therapy for Parkinson's disease is not yet widely available, there have been significant advancements in preclinical and clinical research. One of the most notable examples is the ongoing clinical trial of AAV2-GDNF gene therapy, led by researchers at the University of Bristol. This trial involves delivering the GDNF gene into the brains of Parkinson's patients using an Adeno-Associated Virus (AAV) vector. Early results have shown promising improvements in motor function and quality of life.

Challenges and considerations

While Parkinson's gene therapy shows promise, several challenges must be addressed before it can become a standard treatment. Ensuring the safety of gene therapy is paramount. Researchers need to minimize the risk of unintended consequences, such as off-target gene editing or immune responses to the viral vectors used for gene delivery [3]. Parkinson's is a progressive disease, so gene therapy must provide long-term benefits. Researchers are working to determine the durability of gene-based interventions. The successful delivery of therapeutic genes to the brain is a significant challenge. Different approaches, such as intravenous injection or direct injection into the brain, are being explored to optimize delivery [5-11]. Gene therapy raises ethical questions, including issues related to consent, accessibility, and the potential for genetic enhancement. Regulatory agencies must establish guidelines to ensure the responsible development and deployment of these therapies [12,13].

Conclusion

Parkinson's gene therapy is an exciting and rapidly evolving field of research that holds the potential to revolutionize the treatment of this debilitating disease. While there are still hurdles to overcome, early clinical trials and preclinical studies have provided encouraging results. As researchers continue to refine gene therapy techniques and address safety concerns, there is hope that gene therapy may one day offer a viable treatment option for individuals living with Parkinson's disease. Ultimately, the progress in this field offers a glimmer of hope for a future where Parkinson's disease can be effectively managed or even cured.

References

1. Zhang ZX, Roman GC, Hong Z, Wu CB, Qu QM, et al. (2005). Parkinson's disease in China: prevalence in Beijing, Xian, and Shanghai. Lancet 365(9459):595-597.
2. Lin MK, Farrer MJ (2014). Genetics and genomics of Parkinson's disease. Genome medicine. Annu Rev Pathol 6:1-6.
3. Bogdan R, Salmeron BJ, Carey CE, Agrawal A, Calhoun VD, et al. (2017). Imaging genetics and genomics in psychiatry: a critical review of progress and potential . Biol Psychiatry82(3):165-175.
4. Subramaniam SR, Chesselet MF (2013). Mitochondrial dysfunction and oxidative stress in Parkinson's disease. Prog Neurobiol 106:17-32.

5. Tinaz S, Kamel S, Aravala SS, Elfil M, Bayoumi A, et al. (2022) Neurofeedback-guided kinesthetic motor imagery training in Parkinson's disease: Randomized trial. Neuroimage Clin 34:102980.
6. Rajesh T. (2015) Effects of Motor Imagery on Upper Extremity Functional Task Performance and Quality of Life among Stroke Survivors. Disability, CBR & Inclusive Development 26(1): 109-124.
7. Caligiore D, Mustile M, Spalletta G, Baldassarre G (2017) Action observation and motor imagery for rehabilitation in parkinson's disease: A systematic review and an integrative hypothesis. Neurosci Biobehav Rev 72:221-222.
8. Tomlin G, Borgetto B (2011) Research Pyramid: A new evidence-based practice model for occupational therapy. Am J Occup Ther 65(2): 189-196.
9. Huang HC, Chen CM, Lu MK, Liu BL, Li CI, et al. (2021) Gait-related brain activation during motor imagery of complex and simple ambulation in parkinson's disease with freezing of gait. Front Aging Neurosci 22;13:731332.
10. Shapiro L (2022) Virtual reality, motor imagery plus PT ease Parkinson's motor symptoms.
11. Abraham A, Hart A, Andrade I, Hackney ME (2018) Dynamic neuro-cognitive imagery improves mental imagery ability, disease severity, and motor and cognitive functions in people with Parkinson's disease. Neural Plast 6168507.
12. Nascimento IAP da S, Santiago LM de M, de Souza AA, Pegado C de L, Ribeiro TS, et al. (2019) Effects of motor imagery training of Parkinson's disease: A protocol for a randomized clinical trial. BioMed Central Trials 20(1):626.
13. Tamir R, Dickstein R, Huberman M (2007) Integration of motor imagery and Physical practice in Group Treatment Applied to Subjects With Parkinson's Disease. Neurorehabil Neural Repair 21(1):68-75.